厄贝沙坦联合胰激肽原酶治疗老年早期糖尿病肾病的观察  

Combined therapy of kallidinogenase and irbesartan for early period type 2 diabetic nephropathy of elderly patients

作　　者：许腾[1] 胡军[1] 刘霞[1] 廖丹[1] 高啸[1] 

机构地区：[1]华中科技大学同济医学院附属梨园医院内分泌科,湖北武汉430077

出　　处：《中国医院药学杂志》2009年第17期1472-1475,共4页Chinese Journal of Hospital Pharmacy

摘　　要：目的:观察厄贝沙坦联合胰激肽原酶治疗老年早期糖尿病肾病(DN)的疗效。方法:72例早期DN患者随机分成3组,观察组(厄贝沙坦联合胰激肽原酶),ARB组(厄贝沙坦)及对照组各24例;观察12周,比较治疗前后患者尿微量白蛋白排泄率(UAER)、尿β2-微球蛋白(β2-MG)、平均动脉压(MAP)、血清肌酐(Scr)及糖化血红蛋白(HbA1c)变化。结果:治疗后观察组及ARB组UAER及尿β2-MG较治疗前显著下降(P<0.01),且较对照组显著降低(P<0.01),观察组较ARB组下降更为显著(P<0.01);3组治疗后MAP较治疗前均有明显下降(P<0.01),三组之间差异无显著性(P>0.05);治疗后观察组及ARB组Scr、HbA1c无明显变化(P>0.05)。结论:厄贝沙坦联合胰激肽原酶治疗老年早期DN疗效确切,可显著减少患者尿蛋白排出。OBJECTIVE To observe the effect of combined therapy of kallidinogenase and irbesartan in early stage type 2 dia- betic nephropathy of elderly patients. METHODS The 72 early stage type 2 diabetic nephropathy were randomly divided into three groups, observation group（irbesartan plus kallidinogenase, n = 24）, ARB group（irbesartan, n = 24） and control group（n = 24）. After 12 weeks, the patients underwent examinations for changes in the urinary albumin excretion rate（UAER）, urine t32 microglobulin（β2-MG） ,mean arterial blood pressure（MAP）,serum creatinine（Scr） and glycosylated hemoglobin（HbAlc） before and after treatment. RESULTS Observation group and ARB group significantly lowered UAER, β2-MG than before（P〈 0. 01）, and had obviously decreases than control group （P〈0. 01）. Observation group produced the most obvious reduction than ARB（P〈0. 01）. The MAP of the three groups had significantly decreases than before. There were no differences among three groups（P〉0. 05）. No obvious changes of the levals of Scr,HbAlc in observation group and ARB group（P〉0. 05）. CONCLUSION Combined therapy of irbesartan and kallidinogenase have good effects in the treatment of early stage type 2 diabetic nephropathy of elderly patients and can obviously reduce urinary albumin excretion.

关 键 词：胰激肽原酶 厄贝沙坦 糖尿病肾病 尿微量白蛋白 

分 类 号：R969[医药卫生—药理学]